Gilbert's syndrome: Difference between revisions

Jump to navigation Jump to search
m (Robot: Changing Category:Disease state to Category:Disease)
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
Line 99: Line 99:
{{Reflist|2}}
{{Reflist|2}}


{{SIB}}
 
{{Endocrine, nutritional and metabolic pathology}}
{{Endocrine, nutritional and metabolic pathology}}
[[de:Morbus Meulengracht]]
[[de:Morbus Meulengracht]]

Revision as of 15:31, 9 August 2012

For patient information click here

Gilbert's syndrome
Bilirubin
ICD-10 E80.4
ICD-9 277.4
OMIM 143500
DiseasesDB 5218
MeSH D005878

WikiDoc Resources for Gilbert's syndrome

Articles

Most recent articles on Gilbert's syndrome

Most cited articles on Gilbert's syndrome

Review articles on Gilbert's syndrome

Articles on Gilbert's syndrome in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Gilbert's syndrome

Images of Gilbert's syndrome

Photos of Gilbert's syndrome

Podcasts & MP3s on Gilbert's syndrome

Videos on Gilbert's syndrome

Evidence Based Medicine

Cochrane Collaboration on Gilbert's syndrome

Bandolier on Gilbert's syndrome

TRIP on Gilbert's syndrome

Clinical Trials

Ongoing Trials on Gilbert's syndrome at Clinical Trials.gov

Trial results on Gilbert's syndrome

Clinical Trials on Gilbert's syndrome at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Gilbert's syndrome

NICE Guidance on Gilbert's syndrome

NHS PRODIGY Guidance

FDA on Gilbert's syndrome

CDC on Gilbert's syndrome

Books

Books on Gilbert's syndrome

News

Gilbert's syndrome in the news

Be alerted to news on Gilbert's syndrome

News trends on Gilbert's syndrome

Commentary

Blogs on Gilbert's syndrome

Definitions

Definitions of Gilbert's syndrome

Patient Resources / Community

Patient resources on Gilbert's syndrome

Discussion groups on Gilbert's syndrome

Patient Handouts on Gilbert's syndrome

Directions to Hospitals Treating Gilbert's syndrome

Risk calculators and risk factors for Gilbert's syndrome

Healthcare Provider Resources

Symptoms of Gilbert's syndrome

Causes & Risk Factors for Gilbert's syndrome

Diagnostic studies for Gilbert's syndrome

Treatment of Gilbert's syndrome

Continuing Medical Education (CME)

CME Programs on Gilbert's syndrome

International

Gilbert's syndrome en Espanol

Gilbert's syndrome en Francais

Business

Gilbert's syndrome in the Marketplace

Patents on Gilbert's syndrome

Experimental / Informatics

List of terms related to Gilbert's syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Gilbert's syndrome (pr. Zhil-bear), often shortened to the acronym GS, is the most common hereditary cause of increased bilirubin, and is found in up to 5% of the population. The main symptom is otherwise harmless jaundice which does not require treatment, caused by elevated levels of unconjugated bilirubin in the bloodstream (hyperbilirubinemia).

The source of this hyperbilirubinemia is reduced activity of the enzyme glucuronyltransferase which conjugates bilirubin and some other lipophilic molecules. Conjugation renders the bilirubin water-soluble and suitable for excretion via the kidneys.

Eponym

Gilbert's syndrome was first described by French gastroenterologist Augustin Nicolas Gilbert and co-workers in 1901.[1][2]

In German literature, it is commonly associated with Jens Einar Meulengracht.[3]

Pathogenesis

Gilbert's syndrome is caused by approximately 30%-50% reduced glucuronidation activity of the enzyme Uridine-diphosphate-glucuronosyltransferase isoform 1A1 (UGT1A1).[4][5] The gene which encodes UGT1A1 normally has a promoter region TATA box containing the allele A(TA6)TAA. Gilbert's syndrome is associated with homozygous A(TA7)TAA alleles.[6] The allele polymorphism is referred to as UGT1A1*28.

Signs and symptoms

Jaundice

Gilbert's syndrome produces an elevated level of unconjugated bilirubin in the bloodstream but normally this has no serious consequence. Mild jaundice may appear under conditions of exertion, stress, fasting, and infections, but the condition is otherwise usually asymptomatic. [7][8]

It has been reported that GS may contribute to an accelerated onset of neonatal jaundice[9].

Some patients report experiencing unpleasant physical symptoms during episodes of high bilirubin levels. They may report meal-related fatigue, tremors, nausea, and abdominal pain, with jaundice.[10] Because patients may be unaware of their condition but conscious of apparent jaundice, they may present these symptoms at urgent-care facilities needlessly.

Detoxification of certain drugs

The enzymes that are defective in GS (UGT1A1) are also responsible for some of the liver's ability to detoxify certain drugs. For example, Gilbert's syndrome is associated with severe diarrhea and neutropenia in patients who are treated with irinotecan, which is metabolized by UGT1A1.[11]

While paracetamol (acetaminophen) is not metabolized by UGT1A1,[12] it is metabolized by one of the other enzymes also deficient in some people with GS.[13][14] A subset of people with GS may have an increased risk of paracetamol toxicity.[14][15]

Debated signs and symptoms

Reduced risk of ischemic heart disease

One research group in the Czech Republic has found a reduced incidence of atherosclerotic disease in subjects with GS[16]. This is supposed to be due to bilirubin IXα being recognised as a potent antioxidant [17].

Diffuse symptoms

Many people report diffuse symptoms related to GS - feeling tired all the time (fatigue), difficulty maintaining concentration, loss of appetite, abdominal pain, loss of weight and others - [18], but no clear adverse symptoms related to elevated levels of unconjugated bilirubin have been found in adults during scientific studies.[19][20]. This has led some to dispute whether GS should classify as a disease.[20][21]

Diagnosis

Exclusion of other conditions

While this syndrome is considered harmless, it is clinically important because it may be confused with much more dangerous liver conditions. However, these will show other indicators of liver dysfunction:

  • Hemolysis can be excluded by a full blood count, haptoglobin, lactate dehydrogenase levels and the absence of reticulocytosis (elevated reticulocytes in the blood would usually be observed in haemolytic anaemia).
  • Hepatitis can be excluded by negative blood samples for antigens specific to the different hepatitis vira.
  • Cholestasis can be excluded by the absence of lactate dehydrogenase, low levels of conjugated bilirubin and ultrasound scan of the bile ducts.
  • More severe types of glucoronyl transferase disorders like Crigler-Najjar syndrome (types I and II). These are much more severe, with 0-10% UGT1A1 activity, with sufferers at risk of brain damage in infancy (type I) and teenage years (type II).
  • Other diseases of the liver can be exluded by the liver-enzymes ALT, AST and albumin being within normal ranges.

Normal levels of total bilirubin (conjugated and unconjugated) are under 20 mmol/dL. Patients with GS show predominantly elevated unconjugated bilirubin, while conjugated is usually in normal ranges and form less than 20% of the total. Levels of bilirubin in GS patients should be between 20 mmol/dl and 80 mmol/dl (or, divided by 17.1 to express these numbers in mg/dL, between 1.17 and 4.68 mg/dL). GS patients will have a ratio of unconjugated/conjugated (indirect/direct) bilirubin that is commensurately higher than those without GS. Other liver enzymes are expected to be similar between patients with and without GS. Complete liver enzyme tests are ordered in order to assure the correct diagnosis.

The level of total bilirubin is often increased if the blood sample is taken while fasting.

More severe types of glucoronyl transferase disorders like GS are Crigler-Najjar syndrome (types I and II). These are much more severe and cause brain damage in infancy (type I) and teenage years (type II).

Findings specific to Gilbert's syndrome

Patients with GS show predominantly elevated unconjugated bilirubin, while conjugated is usually within normal ranges and form less than 20% of the total. Levels of bilirubin in GS patients is reported to be from 20 μmol/dl to 90 μmol/dl (1.2 to 5.3 mg/dL)[22] compared to the normal amount of < 20 μmol/dL. GS patients will have a ratio of unconjugated/conjugated (indirect/direct) bilirubin that is commensurately higher than those without GS.

The level of total bilirubin is often increased if the blood sample is taken after fasting for two days[23], and a fast can therefore be useful diagnostically. If the total bilirubin does in fact increase while fasting, the patient can then be given low doses of phenobarbital[24] when fasting has ended, and following samples should show a decrease in total bilirubin toward normal levels.

Synonyms

Alternative, less common names for this disorder are as follows:

  • Familial benign unconjugated hyperbilirubinaemia
  • Constitutional liver dysfunction
  • Familial non-hemolytic non-obstructive jaundice
  • Icterus intermittens juvenilis
  • Low-grade chronic hyperbilirubinemia
  • Unconjugated benign bilirubinemia
  • Morbus Meulengracht

See also

References

  1. Template:WhoNamedIt
  2. Gilbert A, Lereboullet P. La cholemie simple familiale. Sem Med 1901;21:241-3.
  3. Template:WhoNamedIt
  4. Raijmakers MT, Jansen PL, Steegers EA, Peters WH (2000). "Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene". Journal of Hepatology. 33 (3): 348–351. PMID 11019988.
  5. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP; et al. (1995). "The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome". New England Journal of Medicine. 333 (18): 1171–5. PMID 7565971.
  6. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B (1996). "Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome". Lancet. 347 (9001): 578–81. PMID 8596320.
  7. Kasper et al, Harrison's Principles of Internal Medicine, 16th edition, McGraw-Hill 2005
  8. Boon et al, Davidson's Principles & Practice of Medicine, 20th edition, Churchill Livingstone 2006
  9. Bancroft JD, Kreamer B, Gourley GR (1998). "Gilbert syndrome accelerates development of neonatal jaundice". Journal of Pediatrics. 132 (4): 656–60. doi:10.1016/S0022-3476(98)70356-7. PMID 9580766.
  10. "What is Gilbert's Syndrome?". Action on Gilbert's Syndrome.
  11. Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M (2004). "UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer". Br J Cancer. 91 (4): 678–82. doi:10.1038/sj.bjc.6602042. PMID 15280927.
  12. Rauchschwalbe S, Zuhlsdorf M, Wensing G, Kuhlmann J (2004). "Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype". Int J Clin Pharmacol Ther. 42 (2): 73–7. PMID 15180166.
  13. Kohle C, Mohrle B, Munzel PA, Schwab M, Wernet D, Badary OA, Bock KW (2003). "Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians". Biochem Pharmacol. 65 (9): 1521–7. doi:10.1016/S0006-2952(03)00074-1. PMID 12732365.
  14. 14.0 14.1 Esteban A, Pérez-Mateo M (1999). "Heterogeneity of paracetamol metabolism in Gilbert's syndrome". European journal of drug metabolism and pharmacokinetics. 24 (1): 9–13. PMID 10412886.
  15. Mukherjee S. Gilbert Syndrome. eMedicine.com. URL: http://www.emedicine.com/med/topic870.htm. Accessed: October 7, 2007.
  16. Ladislav Novotnýc and Libor Vítek (2003). "Inverse Relationship Between Serum Bilirubin and Atherosclerosis in Men: A Meta-Analysis of Published Studies". Experimental Biology and Medicine (228): 568–571. PMID 12709588.
  17. Vítek L, Jirsa M, Brodanová M; et al. (2002). "Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels". Atherosclerosis. 160 (2): 449–56. doi:10.1016/S0021-9150(01)00601-3. PMID 11849670.
  18. GilbertsSyndrome.com
  19. Gitlin N. (1977). "The clinical presentation of Gilbert's disease in 26 patients". South Africa Medical Journal. 52 (1): 19–20. PMID 888039.
  20. 20.0 20.1 Olsson R, Bliding A, Jagenburg R, Lapidus L, Larsson B, Svärdsudd K, Wittboldt S. (1988). "Gilbert's syndrome--does it exist? A study of the prevalence of symptoms in Gilbert's syndrome". Acta Med Scandinavia. 224 (5): 485–490. PMID 3264448.
  21. Larissa K. F. Temple, Robin S. McLeod, Steven Gallinger, James G. Wright (2001). "Defining Disease in the Genomics Era". Science Magazine. 293 (5531): 807–808. doi:10.1126/science.1062938. PMID 11486074.
  22. Piter J. Bosma, Ph.D., Jayanta Roy Chowdhury, M.D., Conny Bakker, Shailaja Gantla, Ph.D., Anita de Boer, Ben A. Oostra, Ph.D., Dick Lindhout, Ph.D., Guido N.J. Tytgat, M.D., Peter L.M. Jansen, M.D., Ph.D., Ronald P.J. Oude Elferink, Ph.D., and Namita Roy Chowdhury, Ph.D. (1995). "The Genetic Basis of the Reduced Expression of Bilirubin UDP-Glucuronosyltransferase 1 in Gilbert's Syndrome". New England Journal of Medicine. 333: 1171–1175. doi:10.1056/NEJM199511023331802. PMID 7565971.
  23. J L Gollan, C Bateman, B H Billing (1976). "Effect of dietary composition on the unconjugated hyperbilirubinaemia of Gilbert's syndrome". Gut. 17 (17): 335–340. doi:10.1136/gut.17.5.335. PMID 1278716.
  24. N Carulli, M Ponz de Leon, E Mauro, F Manenti, A Ferrari (1976). "Alteration of drug metabolism in Gilbert's syndrome". Gut. 17 (17): 581–587. doi:10.1136/gut.17.8.581. PMID 976795.


Template:Endocrine, nutritional and metabolic pathology de:Morbus Meulengracht it:Sindrome di Gilbert he:תסמונת גילברט hu:Gilbert-szindróma nl:Syndroom van Gilbert sl:Gilbertov sindrom fi:Gilbertin oireyhtymä sv:Gilberts syndrom


Template:WikiDoc Sources